Kunal Desai

714 total citations · 1 hit paper
17 papers, 481 citations indexed

About

Kunal Desai is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Kunal Desai has authored 17 papers receiving a total of 481 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Kunal Desai's work include Renal cell carcinoma treatment (6 papers), Brain Metastases and Treatment (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Kunal Desai is often cited by papers focused on Renal cell carcinoma treatment (6 papers), Brain Metastases and Treatment (5 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Kunal Desai collaborates with scholars based in United States, India and United Kingdom. Kunal Desai's co-authors include Jeffrey M. McManus, Nima Sharifi, Lauren Mashburn‐Warren, Donald A. Morrison, Manmeet S. Ahluwalia, Michael J. Federle, Moshe Chaim Ornstein, Tian Zhang, Landon C. Brown and Yi Xu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Kunal Desai

17 papers receiving 473 citations

Hit Papers

Hormonal Therapy for Prostate Cancer 2021 2026 2022 2024 2021 50 100 150 200 250

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kunal Desai United States 8 217 212 138 98 94 17 481
Wu B China 11 253 1.2× 77 0.4× 136 1.0× 62 0.6× 48 0.5× 35 480
Miguel Marino United States 4 155 0.7× 44 0.2× 192 1.4× 35 0.4× 102 1.1× 4 467
Weiwei Shi China 11 198 0.9× 81 0.4× 128 0.9× 27 0.3× 67 0.7× 21 450
Adriana Freitas Neves Brazil 12 248 1.1× 124 0.6× 27 0.2× 44 0.4× 150 1.6× 27 435
Smita Misra United States 14 368 1.7× 67 0.3× 129 0.9× 50 0.5× 94 1.0× 31 569
Qian An China 14 421 1.9× 41 0.2× 143 1.0× 38 0.4× 123 1.3× 37 645
Tatiana Sedláčková Slovakia 14 319 1.5× 68 0.3× 260 1.9× 42 0.4× 264 2.8× 39 623
S. Carrère France 8 291 1.3× 93 0.4× 68 0.5× 30 0.3× 91 1.0× 9 474
May S. Li Hong Kong 6 406 1.9× 73 0.3× 111 0.8× 45 0.5× 152 1.6× 6 625
Boaz Nachmias Israel 11 451 2.1× 47 0.2× 185 1.3× 32 0.3× 87 0.9× 57 697

Countries citing papers authored by Kunal Desai

Since Specialization
Citations

This map shows the geographic impact of Kunal Desai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kunal Desai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kunal Desai more than expected).

Fields of papers citing papers by Kunal Desai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kunal Desai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kunal Desai. The network helps show where Kunal Desai may publish in the future.

Co-authorship network of co-authors of Kunal Desai

This figure shows the co-authorship network connecting the top 25 collaborators of Kunal Desai. A scholar is included among the top collaborators of Kunal Desai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kunal Desai. Kunal Desai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Desai, Kunal, Anthony V. Serritella, Walter M. Stadler, et al.. (2024). A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 30(11). 2384–2392. 3 indexed citations
2.
Chaudagar, Kiranj, Shenglin Mei, Taghreed Hirz, et al.. (2023). 1537 Androgen blockade primes NLRP3 inflammasome in macrophages to induce tumor cell phagocytosis. SHILAP Revista de lepidopterología. A1760–A1762. 1 indexed citations
3.
Desai, Kunal, Anthony V. Serritella, Walter M. Stadler, et al.. (2023). Phase I trial of enzalutamide (Enz) plus the glucocorticoid receptor antagonist relacorilant (Rela) for patients with metastatic castration resistant prostate cancer.. Journal of Clinical Oncology. 41(16_suppl). 5062–5062. 4 indexed citations
4.
Brown, Landon C., Kunal Desai, Wei Wei, et al.. (2021). Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab. Journal for ImmunoTherapy of Cancer. 9(9). e003281–e003281. 13 indexed citations
5.
Desai, Kunal, Landon C. Brown, Wei Wei, et al.. (2021). A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab. Targeted Oncology. 16(5). 633–642. 12 indexed citations
6.
Desai, Kunal, Jeffrey M. McManus, & Nima Sharifi. (2021). Hormonal Therapy for Prostate Cancer. Endocrine Reviews. 42(3). 354–373. 251 indexed citations breakdown →
7.
Brown, Landon C., Kunal Desai, Tian Zhang, & Moshe Chaim Ornstein. (2020). The Immunotherapy Landscape in Renal Cell Carcinoma. BioDrugs. 34(6). 733–748. 27 indexed citations
8.
Desai, Kunal, Lisa Rybicki, Amanda Nizam, et al.. (2020). Retrospective analysis of immune-related adverse events (irAE) in metastatic renal cell carcinoma (mRCC) patients treated with first-line ipilimumab and nivolumab (I+N).. Journal of Clinical Oncology. 38(15_suppl). e17094–e17094. 1 indexed citations
9.
Brown, Landon C., Kunal Desai, Chester Kao, et al.. (2020). A multicenter retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) and brain metastasis treated with ipilimumab and nivolumab.. Journal of Clinical Oncology. 38(6_suppl). 637–637. 3 indexed citations
10.
Desai, Kunal, Landon C. Brown, Wei Wei, et al.. (2020). Multicenter retrospective analysis of patients with metastatic renal cell carcinoma (mRCC) and bone metastases treated with ipilimumab and nivolumab.. Journal of Clinical Oncology. 38(6_suppl). 648–648. 1 indexed citations
11.
Desai, Kunal, et al.. (2019). The Role of Checkpoint Inhibitors in Glioblastoma. Targeted Oncology. 14(4). 375–394. 30 indexed citations
12.
Desai, Kunal, et al.. (2019). Current Treatment Options for Breast Cancer Brain Metastases. Current Treatment Options in Oncology. 20(3). 19–19. 10 indexed citations
13.
Desai, Kunal, et al.. (2019). Combination of oncolytic viruses and immune checkpoint inhibitors in glioblastoma. SHILAP Revista de lepidopterología. 2(1). 7–7. 3 indexed citations
14.
Thapa, Bicky, Adam Lauko, Kunal Desai, Vyshak Alva Venur, & Manmeet S. Ahluwalia. (2018). Novel Systemic Treatments for Brain Metastases From Lung Cancer. Current Treatment Options in Neurology. 20(11). 48–48. 7 indexed citations
15.
Jasuja, Reema, Georgette L. Suidan, Kunal Desai, et al.. (2016). Rivipansel: A Small Pan-Selectin Antagonist Improves Cerebral Perfusion and Inhibits Leukocyte Adhesion and in Murine Sickle Cell Disease Model. Blood. 128(22). 270–270. 1 indexed citations
16.
Desai, Kunal, Lauren Mashburn‐Warren, Michael J. Federle, & Donald A. Morrison. (2012). Development of Competence for Genetic Transformation of Streptococcus mutans in a Chemically Defined Medium. Journal of Bacteriology. 194(15). 3774–3780. 65 indexed citations
17.
Sastry, Lakshmi, et al.. (2003). Certification assays for HIV-1-based vectors: frequent passage of gag sequences without evidence of replication-competent viruses. Molecular Therapy. 8(5). 830–839. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026